PureForm BioSciences’ sister company, PureForm Global, created the first bio-identical CBD, CBG and, soon to be released, CBN, derived from natural materials, not cannabis. The purity of these compounds is unique in the scientific world. The formulations are ideal for clinical investigations, and produce a singular advantage for the PureForm BioSciences drug discovery teams.
PureForms’ cannabinoids are completely consistent, pure, bio-identical, soluble, and available to BioSciences in unlimited supply, without the seasonal limitations of hemp and cannabis-derived cannabinoids, and without the chemical manufacturing limitations of biosynthetics.
The starting materials for its unique cannabinoids are organic, allowing PureForm Biosciences to achieve a near neutral footprint during production of these pharmaceutical grade compounds. This is in sharp contrast to the intense, resource- and chemical-heavy cultivation and extraction process for cannabinoids derived from cannabis plants. “Pure Form” is more than the company’s name, it is a statement of its approach.
The company is engaged in an asymmetric approach; first, identifying readily available bioactive natural products, and second, developing an efficient semi-synthetic route to natural product scaffolds that are not efficiently available either by isolation or total synthesis.
The resultant natural product libraries are then engaged for a wide range of promising new therapeutic targets through collaborations with the world’s leading academic and research institutions.